NeoGenomics, Inc. (NEO)
NEO moved a median of -0.22% 30 minutes after news, and 0.00% by the close. How NEO actually reacts to news — the realized, point-in-time move the market made, measured across 406 labeled events over the last three years with zero look-ahead.
NEO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.07% | 45% | 406 |
| 30-min | -0.22% | 44% | 406 |
| 60-min | -0.07% | 48% | 406 |
| to close | 0.00% | 50% | 401 |
| Middle 50% of NEO reactions | -1.14% to +0.82% |
|---|---|
| Median reaction (30-min) | -0.22% |
| Measured reactions | 406 |
Half of all NeoGenomics, Inc. news events land between -1.14% and +0.82% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NEO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -3.78% | 36% | -2.79% |
| Analyst downgrades | 16 | -1.82% | 38% | -0.85% |
| Rating reiterations | 72 | -0.12% | 46% | -0.43% |
| Price-target raises | 12 | -1.01% | 25% | -1.19% |
| Price-target cuts | 18 | +0.23% | 61% | +0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how NEO ranks against every other measured name →
That’s how NEO usually reacts — get an email when it moves on news →Email me when NEO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NEO's baseline. Nothing else.
Recent NEO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026 | Press release | Business Wire | — | — | |
| Form 8-K NEOGENOMICS INC For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -3.15% | -17.48% | |
| NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan | Press release | Business Wire | -3.15% | -17.48% | |
| NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | Business Wire | +1.27% | -1.25% | |
| NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring | Press release | Business Wire | +2.52% | +4.43% | |
| Form S-8 NEOGENOMICS INC | SEC filing · Form S-8 | SEC EDGAR | +0.42% | +4.07% | |
| Form 8-K NEOGENOMICS INC For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | +0.12% | |
| Form 10-Q NEOGENOMICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.55% | -1.48% | |
| Form 8-K NEOGENOMICS INC For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | -1.48% | |
| NeoGenomics Reports Second Quarter 2026 Results | Press release | Business Wire | -0.55% | -1.48% | |
| Form 8-K/A NEOGENOMICS INC For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -2.10% | |
| Form 8-K NEOGENOMICS INC For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | +1.76% | |
| NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS | Press release | Business Wire | -0.07% | +1.76% | |
| NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer | Press release | Business Wire | +0.00% | +3.37% | |
| NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 | Press release | Business Wire | +0.56% | -3.91% | |
| Form 8-K NEOGENOMICS INC For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +4.34% | +6.43% | |
| NeoGenomics Appoints Carolyn Starrett to its Board of Directors | Press release | Business Wire | +4.34% | +6.43% | |
| Form 8-K NEOGENOMICS INC For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +2.96% | |
| Form 8-K NEOGENOMICS INC For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -1.71% | |
| NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes | Press release | Business Wire | -0.10% | -1.71% | |
| Form 8-K NEOGENOMICS INC For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | +1.84% | |
| NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes | Press release | Business Wire | -0.73% | +1.84% | |
| NeoGenomics to Present New Research at ASCO Annual Meeting 2026 | Press release | Business Wire | -0.32% | +0.22% | |
| Form 8-K NEOGENOMICS INC For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | +0.22% | |
| NeoGenomics to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.30% | -1.79% | |
| Form 10-Q NEOGENOMICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.59% | -12.41% | |
| Form 8-K NEOGENOMICS INC For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -4.59% | -12.41% | |
| NeoGenomics Reports First Quarter 2026 Results | Press release | Business Wire | -4.59% | -12.41% | |
| NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration | Press release | Business Wire | -2.21% | -2.71% | |
| NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 | Press release | Business Wire | +1.64% | +4.99% | |
| NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 | Press release | Business Wire | +0.25% | +0.37% | |
| Form ARS NEOGENOMICS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.25% | +0.37% | |
| Form DEF 14A NEOGENOMICS INC For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.25% | +0.37% | |
| Form DEFA14A NEOGENOMICS INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.25% | +0.37% | |
| NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling | Press release | Business Wire | -0.44% | +2.62% | |
| NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types | Press release | Business Wire | -0.14% | +0.72% | |
| NeoGenomics to Participate in Upcoming Investor Conferences | Press release | Business Wire | -3.81% | -10.08% | |
| Form 10-K NEOGENOMICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.81% | -10.08% | |
| Form 8-K NEOGENOMICS INC For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | +8.95% | |
| NeoGenomics Reports Fourth Quarter and Full Year 2025 Results | Press release | Business Wire | -1.91% | +8.95% | |
| NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection | Press release | Business Wire | -0.39% | -3.62% | |
| NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 | Press release | Business Wire | +0.89% | +0.32% | |
| Form 8-K NEOGENOMICS INC For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +1.66% | -5.81% | |
| NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue | Press release | Business Wire | +1.66% | -5.81% | |
| NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.36% | +2.81% | |
| Form 8-K NEOGENOMICS INC For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | +0.16% | |
| NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors | Press release | Business Wire | +0.31% | +0.16% | |
| NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation | Press release | Business Wire | +0.00% | +0.00% | |
| NeoGenomics to Present New ctDNA Research at SABCS 2025 | Press release | Business Wire | -1.26% | +0.50% | |
| NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 | Press release | Business Wire | +0.17% | -2.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NEO section they belong to.
Where else NEO is measured.
NEO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Align Technology, Inc. (ALGN) | 407 | -0.00% | 50% |
| ALLIQUA BIOMEDICAL (ALQA) | 407 | -0.11% | 43% |
| Vericel Corporation (VCEL) | 406 | -0.19% | 40% |
| SPRING BANK PHARMACEUTICALS (SBPH) | 404 | 0.00% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NeoGenomics, Inc.'s median reaction calculated?
Every labeled NEO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 406 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of NEO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NEO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.